Argus raises Exelon stock price target on rate increases By Investing.com

Exelon reported FY2025 adjusted EPS of $2.76 (+11% y/y) and Q4 EPS of $0.59, beating consensus (~$0.54–$0.57) with annual revenues up ~5%, and provided 2026 EPS guidance of $2.81–$2.91. Argus raised its price target to $52 from $48 and kept a Buy rating; Exelon raised its quarterly dividend by 5% (current yield 3.52% vs peer 3.2%) and has 56 consecutive years of dividends. The company issued $775M of 4.95% notes due 2036 to refinance debt, launched a $60M customer relief fund, and won PJM approval for a 220-mile, 765-kV transmission project—regulatory rate increases continue to drive near-term results.

Analysis

Regulatory ratemaking continues to be Exelon’s primary value driver — the market is pricing a multi-year, low-volatility cashflow stream tied to ratebase growth rather than commodity cycles. That shifts the beat from generation economics to execution risk on capital projects (transmission buildouts) and the cadence of rate case wins; contractors, tower/steel suppliers and regional engineering firms become de facto beneficiaries as capex ramps.

Credit markets are the marginal arbiter of utility valuation now: long-dated issuance appetite determines how much of Exelon’s future capex is locked in at attractive coupons. A modest move higher in Treasury yields or a sector-specific spread widening could meaningfully compress equity multiples because regulated earnings are capital-intensive with long-duration cashflows. Expect spread volatility to show up in both equity and bond performance over a 6–24 month window.

Key downside scenarios are simple but impactful — regulatory reversals, material cost overruns on the 765‑kV build, or successful legal challenges delaying PJM interconnection approvals — any of which would push out cash returns and strain credit metrics. Conversely, consecutive favorable rate case outcomes and constructive credit markets would re-rate the equity higher but leave upside capped by allowed ROE frameworks and the utility multiple compression that follows certainty.

The consensus tilt toward “safer utility” positioning understates execution and funding risk; investors should treat Exelon as a regulated growth-with-duration story, not a bond proxy. Monitor upcoming rate filings, FERC/PJM docket activity, and the next 12–18 months of issuance cadence — those are the highest information-density triggers for P&L moves.

Key Decisions for Investors

• Long EXC equity (accumulate over 3–6 months). Target a 20–30% total return over 12–24 months if regulatory outcomes remain constructive; hard stop if shares fall 15% from entry or if two consecutive material rate-case outcomes miss expectations. Use position size such that a 15% drawdown equals a single-digit percent portfolio move.
• Buy EXC long-dated corporate paper (EXC 2036 notes) on any secondary weakness; expected payoff is stabilization of funding cost and carry while capex is deployed. Hold 3–8 years; downside is a parallel move up in global rates — hedge duration risk with short-duration Treasuries or interest-rate swaps if duration exposure exceeds portfolio limits.
• Options collar to express asymmetric upside: buy EXC Jan 2027 calls (1–2 year tenor) sized for desired upside and finance with short near-term calls (3–6 months) to collect premium. This lets you participate in re-rating from rate-case wins while capping near-term cost — target 2.5:1 upside/downside skew and cut if implied vol rises >40% from current.
• Relative-value pair: long EXC / short an unregulated merchant generator or merchant-heavy utility to isolate regulatory ratebase premium (use equal-$ notional). Timeframe 6–18 months; expected R/R is moderate (10–25%) from mean reversion if regulatory tailwinds are confirmed, but watch for sector-wide rate moves which can invalidate the spread — exit if pair spread tightens/widens beyond historical 1.5x SD.